



VIRTUAL CONFERENCE
UPDATE IN HEADACHE 2020

DEC | 2020
18 | to 2021

DISCLOSURE

PROGRAM OVERVIEW

In the United States, 1.4% of all visits to office-based physicians are due to headache, which represents approximately 12 million physician visits in one year. According to recent studies, 8.7 million females and 2.6 million males in the US alone experience migraine. Existing and ongoing research activity in the field of headache has produced clinical data of which primary care providers should be cognizant in order to provide optimal care to headache sufferers. These data have significant implications for diagnosis and treatment and may challenge current assumptions about the role of healthcare professionals in the management of primary headache disorders. Practitioners should be knowledgeable about new findings concerning pharmacological agents used for the treatment of headache, including new formulations of existing medications and those recently available for headache management.

LEARNING OBJECTIVES

After participating in this educational activity, participants should be better able to

1. Identify the common categories of headache.
2. Incorporate the differential diagnoses of headache disorders in order to choose the best treatment strategies.
3. Develop and implement treatment plans in line with standards of practice for acute management of migraine.
4. Develop and implement preventive treatment as migraine is progressing and transforming.
5. Recognize the characteristic clinical presentations of headache in children and identify the challenges of treating the pediatric patient with chronic migraine.

ACCREDITATION/DESIGNATION STATEMENTS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Forefront Collaborative and Diamond Headache Clinic Research & Educational Foundation. Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME

Forefront Collaborative designates this enduring material for a maximum of 2.75 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

AAP

Application for CME credit has been filed with the American Academy of Pediatrics. Determination of credit is pending.

VIRTUAL CONFERENCE

UPDATE IN HEADACHE 2020

DEC 18 | 2020
to 2021

CERTIFICATES

To receive your CME certificate or your certificate of participation, you MUST complete the Forefront Collaborative online evaluation form. You may access the evaluation form at <https://forefrontcollab.mededmanager.com/evaluation/number/54580>. **The evaluation opens on Friday, December 18, 2020, and must be completed by Saturday, December 18, 2021.**

- ▶ Your certificate will generate in a new tab immediately upon completion of the evaluation, so be ready to print and/or save your certificate at that time
- ▶ A copy of your certificate will be emailed to you upon completion of the evaluation as well as be available in the account you created and can be accessed at any time in your dashboard

UNLABELED USE DECLARATION

During their presentation, faculty may discuss unlabeled or investigational uses that are not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use.

STATEMENT OF DISCLOSURE AND INDEPENDENCE

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of the event.

**The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.*

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

REVIEW COMMITTEE

In accordance with Forefront Collaborative policy, all content is reviewed by independent peer reviewers for balance, objectivity and commercial bias. The review committee includes the following reviewers/editors: **Mark Green, MD, FAAN** and **George Urban, MD**

FACULTY/PLANNING COMMITTEE DISCLOSURES

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

FACULTY: **Jack Gladstein, MD, Robert Kaniecki, MD, Vincent Martin, MD,** and **Traci Purath, MD**

INDEPENDENT PEER REVIEWER: **Mark Green, MD, FAAN**

PLANNERS: **Jacquelyn Fernandez** and **Leah Johnson**

VIRTUAL CONFERENCE

UPDATE IN HEADACHE 2020

DEC 18 | 2020
to 2021

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

FACULTY

Jessica Ailani, MD

Consulting Fee: Amgen, Biohaven Pharmaceuticals, Impel, Eli Lilly Co., Lundbeck Pharmaceuticals, Revance, Satsuma, Teva Pharmaceuticals, Zosano

Speakers Bureau: Allergan, Amgen, Biohaven Pharmaceuticals, Eli Lilly Co., Lundbeck Pharmaceuticals, Teva Pharmaceuticals

Advisory Board: Allergan, Biohaven Pharmaceuticals, Impel, Eli Lilly Co., Teva Pharmaceuticals, Zosano

Contracted Research: Allergan, American Migraine Foundation, Biohaven Pharmaceuticals, Eli Lilly Co., Zosano

Merle Diamond, MD

Independent Contract Writer: Lundbeck Pharmaceuticals

Consulting Fee: Eli Lilly Co., Amgen, Lundbeck Pharmaceuticals, Teva Pharmaceuticals, Biohaven Pharmaceuticals, Upsher-Smith Laboratories

Speakers Bureau: Eli Lilly Co., Amgen, Lundbeck Pharmaceuticals, Teva Pharmaceuticals, Biohaven Pharmaceuticals, Assertio Therapeutics

Advisory Board: Axsome Therapeutics, Supernus Pharmaceuticals, Eli Lilly Co., Amgen, Lundbeck Pharmaceuticals, Teva Pharmaceuticals, Biohaven Pharmaceuticals, Upsher-Smith Laboratories, Assertio Therapeutics and Biohaven Pharmaceuticals

Contracted Research: Amgen, Lundbeck Pharmaceuticals, Teva Pharmaceuticals

Christopher Rhyne, MD

Speakers Bureau: AbbVie, Allergan, Amgen, Biohaven Pharmaceuticals, Eli Lilly Co., Teva Pharmaceuticals, National Headache Foundation

INDEPENDENT PEER REVIEWER

George Urban, MD

Speakers Bureau: Allergan, Amgen/Novartis, Teva Pharmaceuticals

Advisory Board: Alder, Allergan, Biohaven Pharmaceuticals, Promius

PLANNERS

Konrad Kothmann

Consulting Fee: Alder (Lundbeck Pharmaceuticals), Allergan, Amgen, Eli Lilly Co., Novartis, Teva Pharmaceuticals

Speakers Bureau: Allergan, Amgen

Advisory Board: Amgen, Lundbeck Pharmaceuticals, Novartis

Contracted Research: Alder (Lundbeck Pharmaceuticals), Allergan, Amgen, Eli Lilly Co., Novartis

Lilia Zurkovsky

Stock Ownership: Teva Pharmaceuticals